
The regulatory framework governing therapeutic vapes
Prescriber Information Hub The regulatory framework governing therapeutic vapes Since 2021, vapes may...
Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022. Link
Chaiton, M., et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open. 2016;6(6). DOI
Borland, R., et al. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control Four Country cohort survey: Prevalence of quitting activity among smokers. Addiction. 2012;107(3):673-682. DOI
Borland, R., et al. Motivational factors predict quit attempts but not maintenance of smoking cessation: findings from the International Tobacco Control Four country project. Nicotine & Tobacco Research. 2010 Oct;12 Suppl(Suppl 1). DOI
Cooper, J., et al. Australian and New Zealand Journal of Public Health. 2011;35:368–376. DOI
Dono, J., et al. The Lancet Regional Health – Western Pacific. 2022;19:100342. DOI
Fagerström, K. O., et al. Addictive Behaviors. 2014;39:507–511. DOI
Hawkins, J., et al. Long-term smoking relapse: a study using the British Household Panel Survey. Nicotine & Tobacco Research. 2010 Dec;12(12):1228-35. DOI
Coleman, S. R. M., Piper, M. E., Byron, M. J., et al. Dual Use of Combustible Cigarettes and E-cigarettes: A Narrative Review of Current Evidence. Current Addiction Reports. 2022;9:353–362. DOI
Balfour, D. J. K., Benowitz, N. L., Colby, S. M., et al. Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health. 2021;111(8). DOI
Jackson, S. E., et al. JAMA Network Open. 2024;7. DOI
Stead, L. F., Perera, R., Bullen, C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2012;(11). DOI
Lindson, N., Chepkin, S. C., Ye, W., Fanshawe, T. R., Bullen, C., Hartmann-Boyce, J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2019. DOI
Abrams, D. B., Glasser, A. M., Villanti, A. C., Pearson, J. L., Rose, S., Niaura, R. S. Managing nicotine without smoke to save lives now: Evidence for harm minimization. Preventive Medicine. 2018;117:88-97. DOI
Hajek, P., Pittaccio, K., Pesola, F., Myers Smith, K., Phillips Waller, A., Przulj, D. Nicotine delivery and users’ reactions to Juul compared with cigarettes and other e-cigarette products. Addiction. 2020;115(6):1141-1148. DOI
Prochaska, J. J., Vogel, E. A., Benowitz, N. Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control. 2021. DOI
O’Connell, G., Pritchard, J. D., Prue, C., et al. A randomized, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers. Internal and Emergency Medicine. 2019;14(6):853-861. DOI
Hajek, P., Phillips-Waller, A., Przulj, D., et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. New England Journal of Medicine. 2019;380(7):629-637. DOI
Myers Smith, K., Phillips Waller, A., Pesola, F., et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomized controlled trial. Addiction. 2021. DOI
Shifman, S., Sembower, M. A., Augustson, E. M., et al. The Adult JUUL Switching and Smoking Trajectories (ADJUSST) Study: Methods and Analysis of Loss-to-Follow-up. American Journal of Health Behavior. 2021;45(3):419-442. DOI
Prakash, S., Hatcher, C., Shifman, S. Prevalence of ENDS and JUUL Use, by Smoking Status, in National Samples of Young Adults and Older Adults in the U.S. American Journal of Health Behavior. 2021;45(3):402-418. DOI
McNeill, A., Brose, L. S., Calder, R., Simonavicius, E., Robson, D., King’s College London. Vaping in England: An Evidence Update Including Vaping for Smoking Cessation, February 2021. Public Health England; 2021:247. Link
Shifman, S., Ferguson, S. G., Rohay, J., Gitchell, J. G. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction. 2008;103(8):1371-1378. DOI
RACGP. Optimising Nicotine Replacement Therapy in Clinical Practice. The Royal Australian College of General Practitioners. Accessed September 22, 2021. Link
Przulj, D., Hajek, P., Phillips-Waller, A. E-Cigarettes versus Nicotine-Replacement Therapy for Smoking Cessation. New England Journal of Medicine. 2019;380(20):1973-1975. DOI
Shifman, S., Sembower, M. A. Dependence on e-cigarettes and cigarettes in a cross-sectional study of US adults. Addiction. 2020;115(10):1924-1931. DOI
Kimber, C. F., Soar, K., Dawkins, L. E. Changes in puffing topography and subjective effects over a 2-week period in e-cigarette naïve smokers: Effects of device type and nicotine concentrations. Addictive Behaviors. 2021;118:106909.
Prescriber Information Hub The regulatory framework governing therapeutic vapes Since 2021, vapes may...
Pharmacist Information Hub The scientific consensus on vaping The gold standard for understanding...
Prescriber Information Hub Understanding the current vaping laws GPs have prescribed vaping products...
Prescriber hub S3 vapes: Why GP visits are likely to increase from...
Prescriber hub Standards framework for the new Nicovape® Q System Prescriber hub...
Prescriber hub Questions you need to ask before prescribing an NVP brand...
Prescriber hub PNVP References Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022....
Prescriber hub Frequently Asked Questions Is Nicovape® Q Safe? There isn’t enough...
Prescriber hub Helping your patient start using Nicovape® Q Setting up your...
This website is a source of educational content for Australian-registered healthcare professionals only. You must not use the content for any other purpose. If you are a patient seeking medical advice please see your healthcare professional.
By accessing this website you are agreeing that you are an Australian-registered healthcare professional with a current AHPRA registration and are entitled to access this content. Your use of this content is also subject to our Terms of Use and Privacy Policy.
With low-concentration vapes becoming S3 from 1 October 2024, there is much confusion as to what is expected of pharmacists, and how the market is likely to play out.
Liber Pharmaceuticals has worked closely with thousands of pharmacists and prescribers for the last three years to ensure that you are able to supply therapeutic vapes effectively.
Join us as we share our thoughts on the following:
Each session will have at least 30 minutes for Q&A.